Biomimetic Dual-Multivalent Strategy Enabled In Vivo Tumor-Targeted Molecular MRI.

Area of Science:

• Biomedical Imaging
• Nanotechnology
• Materials Science

Background:

• Magnetic resonance (MR) imaging is crucial for cancer detection but faces limitations in sensitivity, specificity, and contrast.
• Current MR contrast agents often lack sufficient tumor targeting and signal enhancement.

Purpose of the Study:

• To design a novel dual-multivalent MR contrast agent for enhanced tumor visualization and detection.
• To overcome the limitations of existing MR contrast agents through a molecular dual-multivalent enhancement strategy.

Main Methods:

• Developed a tetra-armed macrocyclic gadolinium(III)-based molecular MR contrast agent (GdCAG).
• Incorporated four carboxylic alkyl arms and four glucosyl targeting ligands for simultaneous relaxivity enhancement and tumor recognition.
• Evaluated GdCAG's performance in healthy mice and 4T1 breast cancer xenograft models.

Main Results:

• GdCAG demonstrated significantly improved MR relaxivity and enhanced tumor affinity compared to monomultivalent analogues and clinical controls.
• Intravenous administration of GdCAG resulted in effective in vivo tumor-targeted MR imaging with prolonged signal retention.
• GdCAG showed progressive MR signal increase at tumor sites in xenograft models, indicating superior tumor-targeting efficacy.

Conclusions:

• The molecular dual-multivalent enhancement paradigm offers a promising approach for advancing tumor-specific MR contrast agent design.
• GdCAG has broad potential for improving early cancer diagnosis, precision bioimaging, and image-guided therapies.